DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Improving Tumor Oxygenation in Cervical Cancer

Information source: University of California, Irvine
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Cervical Cancer

Intervention: Methazolamide (Drug); Cisplatin (Drug)

Phase: Phase 2

Status: Withdrawn

Sponsored by: University of California, Irvine

Official(s) and/or principal investigator(s):
Devansu Tewari, MD, Principal Investigator, Affiliation: Chao Family Comprehensive Cancer Center


The Phenomenon of Tumor Hypoxia Many solid tumors are relatively resistant to treatment with ionizing radiation and certain chemotherapeutic agents such as anthracyclines that are affected adversely by acidic pH. These effects have primarily been attributed to the presence of hypoxic cells within the tumor. The relevance of hypoxia with respect to failure of radiotherapy to cure certain malignancies has had a chequered history. However, in recent years the evidence that hypoxia plays a central role in relative radioresistance has become more compelling. Since approximately two-thirds of all women suffering from cervical carcinoma receive radiation as a component of their therapy, an enhanced understanding of the interactions between hypoxia and radiation as a component of their therapy, an enhanced understanding of the interactions between hypoxia and radiation resistance is critical to improving outcome among those with cervical cancer.

Clinical Details

Official title: Improving Tumor Oxygenation in Cervical Cancer With Methazolamide

Study design: Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: To assess the feasibility in improving tumor oxygenation


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Female.


Inclusion Criteria:

- The subject will have a malignant tumor of the cervix which is not curable by surgery

in which it has been determined the subject is to receive the standard care of treatment of radiation therapy and chemotherapy.

- The subject must have adequate bone marrow function, renal function, hepatic function

and neurologic function.

- The subject should be free of active infection requiring antibiotics.

- The subject must have signed the approved informed consent

- If the subject is of childbearing age, they must have a negative urine pregnancy test

with effective contraception

- The subject must have met pre-entry requirements

1. Physical examination to include pelvic examination, blood counts, assessment of liver and kidney status through blood studies 2. A serum pregnancy test 3. Detectable tumor will be measured. Exclusion Criteria:

- The subject has not been clinically staged for their cancer

- The subject has evidence of or is being treated for an active infection

- The subject cannot perform the appropriate follow-up or complete the study for

whatever reason.

- The subject has not consented to an additional tumor biopsy and MRI after my seven

days of treatment with methazolamide

- The subject has evidence of chronic obstructive pulmonary disease

- The subject is currently breastfeeding

- The subject is pregnant

- The subject takes aspirin chronically

- The subject has a history of Stevens-Johnson syndrome

- The subject has not signed the approved informed consent

Locations and Contacts

Additional Information

Starting date: July 2004
Last updated: February 27, 2008

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017